HDR-plesiotherapy for the treatment of anogenital extramammary Paget's disease

Abstract

This technique represents an attractive alternative for those patients who are not candidates for surgical procedures because of unacceptable risk of disfigurements or functional impairment, medical contraindications or patient preference.

Postoperative radiation therapy for extramammary Paget's disease

“…There have been some reports of patients with EMPD treated with brachytherapy as definitive therapy for gross tumours. Marcos et al . treated a patient with anogenital EMPD with high‐dose‐rate (HDR) brachytherapy using an Ir‐192 source.…”

“…There have been some reports of patients with EMPD treated with brachytherapy as definitive therapy for gross tumours. Marcos et al 19 treated a patient with anogenital EMPD with high-dose-rate (HDR) brachytherapy using an Ir-192 source. A total dose of 54 Gy in 12 fractions (three fractions per week for 4 weeks) was delivered to a 5-mm depth from the surface of a custom-made mould positioned in the anogenital region to include the primary tumour.…”

Recalcitrant extramammary Paget's disease treated successfully with high‐dose‐rate brachytherapy: A case series and review of the literature

“…1 Herein, three patients were treated successfully with HDR-BT for EMPD. For our three patients and six known cases of EMPD treated with HDR-BT in the literature, all nine patients sustained clinical remission during a median follow-up of 18 months (range 6-45.7) [4][5][6][7] ; nonetheless, this finding is subject to reporting bias and larger studies are warranted. Our series supports HDR-BT as a possible treatment for EMPD, particularly for cases nonamenable to surgery.…”

Measurement of primary tumor volume by PET–CT to evaluate risk of mediastinal nodal involvement in NSCLC patients with clinically negative N2 lymph nodes

“…Images were reconstructed using 3D iterative reconstruction. 1,2 Whole body images in DICOM formats were sent online via PACS system (Siemens, Erlangen, Germany) to the external beam radiotherapy treatment planning system. Tumor area was identified and delineated on each PET-CT scan by the oncologist with the assistance of a nuclear medicine specialist, who was unaware of clinical and pathological findings.…”